News
Opinion
Resources
Webcasts
Podcasts
White Papers
Events
E-Books
Associations and Organizations
Conferences
Conference Listing
Brand Insights
Subscribe
Advertise

logo
Spotlight
Companion DiagnosticsDigital BiomarkersDigital EndpointsDigital TherapeuticsDrug-Device CombinationsMedical Devices, Class II and Class IIIRWESoftware as a Medical Device
Topic
AIClinical CareCybersecurityData ScienceRemote Patient MonitoringPayersStrategy
News
Opinion
Webcasts
Podcasts
White Papers
Events
E-Books
Associations and Organizations
Conference Listing
Brand Insights
Subscribe
Advertise
Advertisement
AI
| Academic Research
| Clinical Care
| Clinical Trials
| Commercialization
| Companion Diagnostics
| Cybersecurity
| Data Science
| Device Development
| Digital Biomarkers
| Digital Endpoints
| Digital Therapeutics
| Drug-Device Combinations
| Ethics
| Medical Devices (Class II and Class III)
| Patient Engagement
| Payers
| Profiles/Q&A
| RWE
| Regulatory
| Remote Patient Monitoring
| SaMD
| Strategy
| Studies/Published Research
| Virtual Reality
View All >>
  • AI
  • Academic Research
  • Clinical Care
  • Clinical Trials
  • Commercialization
  • Companion Diagnostics
  • Cybersecurity
  • Data Science
  • Device Development
  • Digital Biomarkers
  • Digital Endpoints
  • Digital Therapeutics
  • Drug-Device Combinations
  • Ethics
  • Medical Devices (Class II and Class III)
  • Patient Engagement
  • Payers
  • Profiles/Q&A
  • RWE
  • Regulatory
  • Remote Patient Monitoring
  • SaMD
  • Strategy
  • Studies/Published Research
  • Virtual Reality

SPOTLIGHT -

Companion Diagnostics
| Digital Biomarkers
| Digital Endpoints
| Digital Therapeutics
| Drug-Device Combinations
| Medical Devices, Class II and Class III
| RWE
| Software as a Medical Device

FDA Releases Draft Guidance for Regulatory Considerations for Prescription Drug-Use-Related Software

September 26, 2023
News
Article

The agency differentiates between software that has a notable impact on the effectiveness and safety of drug use.

Pharmaceuticals companies are embracing new technologies that could potentially assist patients with taking medication in a safe and effective manner.

In 2018, FDA began soliciting comments for a possible regulatory framework based around these technologies. In September, 2023, the agency issued its draft guidance on the subject, explaining how drug sponsors should describe their software both in FDA required labeling and promotional labeling.

For the required labeling, which includes prescribing information, the sponsor can submit evidence to FDA that the software results in a meaningful improvement in a clinical outcome as compared to when the patient takes the drug without using the software. If the evidence supports this, the label should include relevant information about the software and its use.

Advertisement

If the software does not have a meaningful outcome on the use of the medication, then it should not be included on required labeling. In that case, the sponsor will simply have to follow the regulations for promotional labeling and ensure that the information presented, such as in a screen display or text message, is accurate, non-misleading, and balanced.

FDA recognizes various types of software as being prescription drug-use related. This can include apps that act as a digital medication log, or a device-connected product that directly transmits drug use related data.

According to a press release from FDA, the agency has mostly seen products that use basic software that mostly focus on providing convenience to the patient. However, the agency also recognizes that this is a growing field and that more and more drug sponsors are adding software functions to prescription drugs and treatments.

As the field continues to grow, the agency will continue to monitor it and work with companies to ensure that the regulations properly products being brought to market.

Source

(Sept. 18, 2023); FDA; Software Associated with Prescription Drugs: Opportunities to Enhance Safe and Effective Medication Use; https://www.fda.gov/drugs/news-events-human-drugs/software-associated-prescription-drugs-opportunities-enhance-safe-and-effective-medication-use

Related Content
Advertisement
FDA Awards Breakthrough Device Designation to Roche's Neurofilament Light Chain Test for MS

FDA Awards Breakthrough Device Designation to Roche's Neurofilament Light Chain Test for MS

November 9th 2023
Articles

The Elecsys NfL test is designed to aid in detecting disease activity and to offer insights in disease management for patients with multiple sclerosis.

stock.adobe.com

FDA Clears Zeta Surgical’s Mixed Reality Navigation System

September 11th 2023
Articles

The device provides surgeons with GPS-like guidance.

Levita Magnetics

FDA Grants Clearance To Levita Magnetics’ Surgery Platform

August 22nd 2023
Articles

The MARS platform combines magnets and machinery.

stock.adobe.com

FDA Designates NyokAssist As A Breakthrough Device

August 22nd 2023
Articles

The device, developed by magAssist, is an interventional ventricular assistance device.

DIA 2023: Medical Device Regulators and Harmonization

DIA 2023: Medical Device Regulators and Harmonization

July 5th 2023
Articles

Session at DIA discusses the International Medical Device Regulators Forum (IMDRF), its importance and how harmonization could be improved by harmonization.

Eric Alexander

Realistic Reasons Why Stakeholders in the Medical Device and Technologies Industries Need to be Prepared for Legal Challenges

July 5th 2023
Articles

Product liability issues can be costly to companies that aren’t prepared for them.

Related Content
Advertisement
FDA Awards Breakthrough Device Designation to Roche's Neurofilament Light Chain Test for MS

FDA Awards Breakthrough Device Designation to Roche's Neurofilament Light Chain Test for MS

November 9th 2023
Articles

The Elecsys NfL test is designed to aid in detecting disease activity and to offer insights in disease management for patients with multiple sclerosis.

stock.adobe.com

FDA Clears Zeta Surgical’s Mixed Reality Navigation System

September 11th 2023
Articles

The device provides surgeons with GPS-like guidance.

Levita Magnetics

FDA Grants Clearance To Levita Magnetics’ Surgery Platform

August 22nd 2023
Articles

The MARS platform combines magnets and machinery.

stock.adobe.com

FDA Designates NyokAssist As A Breakthrough Device

August 22nd 2023
Articles

The device, developed by magAssist, is an interventional ventricular assistance device.

DIA 2023: Medical Device Regulators and Harmonization

DIA 2023: Medical Device Regulators and Harmonization

July 5th 2023
Articles

Session at DIA discusses the International Medical Device Regulators Forum (IMDRF), its importance and how harmonization could be improved by harmonization.

Eric Alexander

Realistic Reasons Why Stakeholders in the Medical Device and Technologies Industries Need to be Prepared for Legal Challenges

July 5th 2023
Articles

Product liability issues can be costly to companies that aren’t prepared for them.

Mission Statement
Advertise
Editorial Information
Contact Us
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.